CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Sees Significant Increase in Short Interest

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) saw a significant growth in short interest in the month of May. As of May 29th, there was short interest totaling 138,254 shares, a growth of 161.2% from the May 14th total of 52,933 shares. Based on an average daily volume of 1,432,012 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are sold short.

CSL Stock Down 0.4%

Shares of OTCMKTS CSLLY traded down $0.08 during trading hours on Friday, hitting $19.06. 270,710 shares of the stock were exchanged, compared to its average volume of 542,919. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 2.57. The company’s fifty day simple moving average is $20.66 and its two-hundred day simple moving average is $39.97. CSL has a 1-year low of $16.01 and a 1-year high of $44.86.

Analysts Set New Price Targets

Several research analysts have recently commented on CSLLY shares. Zacks Research cut shares of CSL from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Citigroup cut shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Canaccord Genuity Group cut shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Finally, Jefferies Financial Group cut shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce”.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.